 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
小木蟲論壇-學術科研互動平臺» 學術交流區(qū)» 論文翻譯 » 論文翻譯求助完結子版 » 急求
| 1 | 1/1 | 返回列表 |
| 查看: 387 | 回復: 0 | ||
[求助]
急求
|
|
Structure-Activity Relationship Studies of Novel Heteroretinoids: Induction of Apoptosis in the HL-60 Cell Line by a Novel Isoxazole-Containing Heteroretinoid Daniele Simoni,*,† Francesco Paolo Invidiata,‡ Riccardo Rondanin,† Stefania Grimaudo,‡ Giuliana Cannizzo,§ Eleonora Barbusca,§ Ferdinando Porretto,§ Nicola D’Alessandro,§ and Manlio Tolomeo§ Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Via Fossato di Mortara 17-19, 44100 Ferrara, Italy, and` Istituto Farmacochimico and Divisione di Ematologia e Servizio A.I.D.S., Policlinico, Universita di Palermo,` 90123 Palermo, Italy Received April 12, 1999 In a search for retinoic acid receptor (RAR and RXR)-selective ligands, a series of isoxazole retinoids was synthesized and evaluated in vitro in transcriptional activation and competition binding assays for RARs and RXRs. In addition, these compounds were evaluated for their differentiating, cytotoxic, and apoptotic activities. In general, these derivatives showed scarcely any binding affinity and were not active in the transcriptional assay. However, among these isoxazole derivatives, the cis-isomer 14b was identified as a potent inducer of apoptosis, and its activity was found to be 6.5 and 4 times superior than that of 13-cis- and 9-cis-retinoic acids, respectively. On the other hand, compound 13b, which has the trans stereochemistry at the double bond, was found not to be active in the apoptotic assay, but it was endowed with appreciable differentiating activity. Therefore, it seems that the different stereochemistry of the double bond may be associated with a different biological activity: potent apoptotic activity for the cis-isomer but differentiating activity for the trans structure. This biological behavior was found, at least in part, for the 9-cis- and 13-cis-retinoic acids with respect to the all-trans- retinoic acid. Thus, structure 14b could offer an interesting model for the design of new compounds endowed with apoptotic activity. Introduction Programmed cell death, or apoptosis, is a genetically encoded process involved in the homeostasis of multi- cellular organisms and in carcinogenesis.1,2 Several cytotoxic drugs employed in the chemotherapy of ma- lignancies cause apoptosis in neoplastic cells,3 but the mechanisms by which these drugs induce apoptosis are not well-understood at the molecular level, although several studies indicate that wild-type p53 oncosup- pressor gene, the Fas/Fas ligand system, and the caspases activation can play a role in drug-induced apoptosis.4-6 Recently, it has been shown that some natural and synthetic retinoids are capable of inducing apoptosis in cancer cell lines, but the mechanism by which retinoids induce apoptosis is still unknown.7-9 The retinoid signal is mediated by two classes of nuclear receptors: the retinoic acid receptors (RARR, -β, and -γ) and the retinoic X receptors (RXRR, -β, and -γ).10 These receptors usually bind as heterodimers to specific DNA sequences and/or interact with other transcriptional regulators, such as AP-1, to regulate gene transcription. The implication of RARs and RXRs in retinoid-induced apoptosis is still unclear; some observations suggest that cell differentiation mediated by retinoic acid is induced by the activation of RAR, whereas activation of RXR seems to be essential for driving cells into apoptosis;11 on the contrary, other authors have demonstrated the involvement of the RAR in apoptosis induced by reti- noids as shown by the inibition of apoptosis after treatment of HL-60 cells with an RARR antagonist.12,13 Moreover, a novel retinoid has been recently described that induces apoptosis with mechanism(s) not involving the nuclear RAR.14 Thus, as a result of the multiplicity of receptors, hormones, and dimerization pathways, it is likely that the many biological effects associated with retinoids are in fact mediated by several distinct pathways. However, the wider use of retinoids in dermatology (principally in the therapy of psoriasis and acne)10,15,16 and in other diseases such as oncology (treatment of carcinomas and for cancer chemoprevention)17,18 has been precluded by unacceptable side effects19 including skin irritation, lipid and bone toxicity, visual effects, and teratogenicity.7,19 To increase the selectivity to the retinoid receptors and to obtain compounds of pharmacological interest, the relationships between structure and retinoid activity have been extensively studied by preparing a large number of geometric isomers as well as conformationally locked and/or restricted analogues, resulting in specific, rigid, three-dimensional configurations.10,19 Taking these considerations into account, we have recently started a study aimed at evaluating the sub- stitution of the benzene ring portion of potent retinoids, such as the so-called “short retinoids” TTNPB and AM580, with a more hydrophilic isosteric heterocycle (i.e. isoxazole or thiophene). This study has identified a new class of interesting isoxazole-containing heter- |
回復此樓» 猜你喜歡
085600 286分 材料求調劑
已經有4人回復
-
求調劑
已經有7人回復
-
275求調劑
已經有10人回復
-
286求調劑
已經有6人回復
-
083000學碩274求調劑
已經有5人回復
-
【求調劑】085601材料工程專碩 | 總分272 |
已經有5人回復
-
275求調劑
已經有13人回復
-
0856，材料與化工321分求調劑
已經有8人回復
-
085701環(huán)境工程，267求調劑
已經有12人回復
-
320分，材料與化工專業(yè)，求調劑
已經有7人回復
相關版塊跳轉
我要訂閱樓主 aisongjing 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 086000調劑 +3 | 7901117076 2026-03-26 | 3/150 |
|
|---|---|---|---|---|
|
|
[考研] 269專碩求調劑 +10 | 金恩貝 2026-03-21 | 10/500 |
|
|
|
[考研] 考研化學308分求調劑 +10 | 你好明天你好 2026-03-23 | 12/600 |
|
|
[考研] 316求調劑 +5 | Pigcasso 2026-03-24 | 5/250 |
|
|
|
[考研] 一志愿吉大071010，316分求調劑 +3 | xgbiknn 2026-03-27 | 3/150 |
|
|
|
[考研]
 一志愿武漢理工，總分321，英一數(shù)二，求老師收留。
+5
|
nnnnnnn5 2026-03-25 | 5/250 |
|
|
|
[考研] 321求調劑 +6 | Ymlll 2026-03-24 | 6/300 |
|
|
|
[考研] 0703化學求調劑 +3 | 丹青奶蓋 2026-03-26 | 5/250 |
|
|
|
[考研] 求調劑 +8 | Auroracx 2026-03-22 | 8/400 |
|
|
|
[考研]
一志愿廈門大學化學學碩307求調劑
+8
|
y7czhao 2026-03-26 | 8/400 |
|
|
|
[考研] 297求調劑 +6 | 田洪有 2026-03-26 | 6/300 |
|
|
|
[考研] 材料277求調劑 +5 | min3 2026-03-24 | 5/250 |
|
|
|
[考研] 309求調劑 +4 | gajsj 2026-03-25 | 5/250 |
|
|
|
[考研] 0854電子信息求調劑 +7 | α____ 2026-03-22 | 9/450 |
|
|
|
[考研] 求調劑 +3 | 李李不服輸 2026-03-25 | 3/150 |
|
|
|
[考研] 一志愿吉大化學322求調劑 +4 | 17501029541 2026-03-23 | 6/300 |
|
|
|
[考研] 284求調劑 +3 | yanzhixue111 2026-03-23 | 6/300 |
|
|
|
[考研] 361求調劑 +3 | Glack 2026-03-22 | 3/150 |
|
|
|
[考研] 276求調劑 +3 | YNRYG 2026-03-21 | 4/200 |
|
|
|
[考研] 求調劑 +5 | Zhangbod 2026-03-21 | 7/350 |
|